Literature DB >> 17391816

Immunogenicity of varying dosages of 7-valent pneumococcal polysaccharide-protein conjugate vaccine in seniors previously vaccinated with 23-valent pneumococcal polysaccharide vaccine.

Lisa A Jackson1, Kathleen M Neuzil, Moon H Nahm, Cynthia G Whitney, Onchee Yu, Jennifer C Nelson, Pat T Starkovich, Maya Dunstan, Barbara Carste, David K Shay, James Baggs, George M Carlone.   

Abstract

In this dose-ranging study 220 seniors who had received the 23-valent pneumococcal polysaccharide (PnPS) vaccine at least 5 years prior to enrollment were assigned to receive one of four volumes (0.1, 0.5, 1 or 2 ml) of 7-valent pneumococcal conjugate (PnC) vaccine or a 0.5 ml dose of 23-valent PnPS vaccine. All participants received a reduced challenge dose of 0.1 ml of PnPS vaccine 1 year after enrollment. There was evidence of a dose response to PnC vaccine and antibody levels in the 1 ml PnC group tended to be significantly higher than in the PnPS group. A booster response to the challenge vaccination was not observed. Administration of a 1 ml dose of PnC vaccine is more immunogenic than 0.5 ml of PnPS vaccine in elderly adults previously vaccinated with PnPS vaccine.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17391816     DOI: 10.1016/j.vaccine.2007.02.062

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  31 in total

1.  Older adults have a low capacity to opsonize pneumococci due to low IgM antibody response to pneumococcal vaccinations.

Authors:  Saeyoung Park; Moon H Nahm
Journal:  Infect Immun       Date:  2010-11-01       Impact factor: 3.441

Review 2.  Pneumococcal vaccine and opsonic pneumococcal antibody.

Authors:  Joon Young Song; M Allen Moseley; Robert L Burton; Moon H Nahm
Journal:  J Infect Chemother       Date:  2013-05-09       Impact factor: 2.211

3.  Protease Inhibitors Do Not Affect Antibody Responses to Pneumococcal Vaccination.

Authors:  Indhira De La Rosa; Iona M Munjal; Maria Rodriguez-Barradas; Xiaoying Yu; Liise-Anne Pirofski; Daniel Mendoza
Journal:  Clin Vaccine Immunol       Date:  2016-06-06

4.  Statement on the Use of Conjugate Pneumococcal Vaccine - 13 Valent in Adults (Pneu-C-13): An Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI).

Authors:  C Quach-Thanh; Ms H Thomas
Journal:  Can Commun Dis Rep       Date:  2013-10-30

5.  Experimental Human Pneumococcal Colonization in Older Adults Is Feasible and Safe, Not Immunogenic.

Authors:  Hugh Adler; Esther L German; Elena Mitsi; Elissavet Nikolaou; Sherin Pojar; Caz Hales; Rachel Robinson; Victoria Connor; Helen Hill; Angela D Hyder-Wright; Lepa Lazarova; Catherine Lowe; Emma L Smith; India Wheeler; Seher R Zaidi; Simon P Jochems; Dessi Loukov; Jesús Reiné; Carla Solórzano-Gonzalez; Polly de Gorguette d'Argoeuves; Tessa Jones; David Goldblatt; Tao Chen; Stephen J Aston; Neil French; Andrea M Collins; Stephen B Gordon; Daniela M Ferreira; Jamie Rylance
Journal:  Am J Respir Crit Care Med       Date:  2021-03-01       Impact factor: 21.405

6.  Modeling of cost effectiveness of pneumococcal conjugate vaccination strategies in U.S. older adults.

Authors:  Kenneth J Smith; Angela R Wateska; Mary Patricia Nowalk; Mahlon Raymund; Bruce Y Lee; Richard K Zimmerman
Journal:  Am J Prev Med       Date:  2013-04       Impact factor: 5.043

7.  Is there a potential role for protein-conjugate pneumococcal vaccine in older adults?

Authors:  Iman Ridda; Daniel M Musher
Journal:  Australas Med J       Date:  2012-04-30

8.  Pneumococcal vaccination in older adults induces antibodies with low opsonic capacity and reduced antibody potency.

Authors:  Jeremy G Schenkein; Saeyoung Park; Moon H Nahm
Journal:  Vaccine       Date:  2008-08-13       Impact factor: 3.641

9.  Effects of ageing and gender on naturally acquired antibodies to pneumococcal capsular polysaccharides and virulence-associated proteins.

Authors:  Birgit Simell; Mika Lahdenkari; Antti Reunanen; Helena Käyhty; Merja Väkeväinen
Journal:  Clin Vaccine Immunol       Date:  2008-07-02

10.  A dose ranging study of 2 different formulations of 15-valent pneumococcal conjugate vaccine (PCV15) in healthy infants.

Authors:  R Rupp; D Hurley; S Grayson; J Li; K Nolan; R D McFetridge; J Hartzel; C Abeygunawardana; M Winters; H Pujar; P Benner; L Musey
Journal:  Hum Vaccin Immunother       Date:  2019-02-15       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.